TAO Synergies (TAOX) Share-based Compensation (2019 - 2026)
TAO Synergies' (TAOX) quarterly Share-based Compensation came in at $241725.0 in Q2 2026, down 58.47% on a YoY basis from $582114.0 in Q2 2025, and up 215.57% quarter-over-quarter from $76600.0 in Q1 2026.
Analysis
TAO Synergies (TAOX) Share-based Compensation (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Share-based Compensation for 8 consecutive years, with $241725.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation fell 58.47% year-over-year to $241725.0; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (down 43.66% YoY), and the FY2025 full-year result was $1.4 million, down 2.59% from the prior year.
- Share-based Compensation advanced to $241725.0 in Q2 2026 per TAOX's latest filing, from $76600.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.0 million in Q4 2023 and bottomed at -$450503.0 in Q2 2024.
- Historically, Share-based Compensation has averaged $714730.1 across 5 years, with a median of $489538.5 in 2022.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation plunged 234.71% in 2024, then soared 1965.25% in 2026.
- Over 5 years, Share-based Compensation stood at $1.5 million in 2022, then jumped by 231.24% to $5.0 million in 2023, then tumbled by 71.74% to $1.4 million in 2024, then slumped by 46.5% to $753680.0 in 2025, then plunged by 67.93% to $241725.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $241725.0, $76600.0, and $753680.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | 83.34 Mn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | 241,725.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 241,725.00 |
| Mar 31, 2026 | 76,600.00 |
| Dec 31, 2025 | 753,680.00 |
| Sep 30, 2025 | 53,767.00 |
| Jun 30, 2025 | 582,114.00 |
| Mar 31, 2025 | 3,709.00 |
| Dec 31, 2024 | 1.41 Mn |
| Sep 30, 2024 | 3,791.00 |
| Jun 30, 2024 | -450,503.00 |
| Mar 31, 2024 | 468,330.00 |
| Dec 31, 2023 | 4.98 Mn |
| Sep 30, 2023 | 15,064.00 |
| Jun 30, 2023 | 334,416.00 |
| Mar 31, 2023 | 644,781.00 |
| Dec 31, 2022 | 1.50 Mn |
| Sep 30, 2022 | 510,747.00 |
| Jun 30, 2022 | 1.02 Mn |
| Mar 31, 2022 | 711,558.00 |
| Dec 31, 2021 | 1.36 Mn |
| Sep 30, 2021 | 1.20 Mn |